- Home
- KNSA vs NAVI Comparison
KNSA vs NAVI Comparison
Compare KNSA & NAVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KNSA | NAVI |
|---|---|---|
| Founded | 2015 | 1973 |
| Country | United Kingdom | United States |
| Employees | N/A | 670 |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 771.2M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | KNSA | NAVI |
|---|---|---|
| Price | $46.37 | $8.06 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 7 | 7 |
| Target Price | ★ $55.29 | $12.14 |
| AVG Volume (30 Days) | 574.8K | ★ 921.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.89% |
| EPS Growth | ★ 225.00 | N/A |
| EPS | ★ 0.75 | N/A |
| Revenue | ★ $677,564,000.00 | N/A |
| Revenue This Year | $38.01 | $82.46 |
| Revenue Next Year | $17.42 | $12.45 |
| P/E Ratio | $61.77 | ★ N/A |
| Revenue Growth | ★ 60.09 | N/A |
| 52 Week Low | $18.26 | $7.91 |
| 52 Week High | $49.12 | $16.07 |
Technical Indicators
Market Signals| Indicator | KNSA | NAVI |
|---|---|---|
| Relative Strength Index (RSI) | 55.14 | 19.05 |
| Support Level | $40.47 | N/A |
| Resistance Level | $46.48 | $13.34 |
| Average True Range (ATR) | 2.16 | 0.31 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 64.75 | 9.29 |
Price Performance
Historical ComparisonAbout KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
About NAVI Navient Corporation
Navient Corp provides technology-enabled education finance solutions that simplify complex programs and help millions of people achieve success. The company operates its business in two segments: Federal Education Loans, and Consumer Lending. A majority of its revenue is generated from the Federal Education Loans segment, in which the company owns and manages the Federal Family Education Loan Program (FFELP) loans, generating revenue mainly in the form of net interest income. The Consumer Lending segment owns and manages private education loans and is the master servicer for these portfolios. Through its Earnest brand, the company also refinances and originates in-school private educational loans.